FDA grants priority review for Roche ’s Actemra/RoActemra (tocilizumab) supplemental biologics license application for giant cell arteritis, a form of vasculitis
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental biologics license application (sBLA) for Actemra/RoActemra (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition. (Source: Roche Investor Update)
Source: Roche Investor Update - January 24, 2017 Category: Pharmaceuticals Source Type: news

ACNA Titers in Vasculitis Decline with B Cell Therapy (CME/CE)
(MedPage Today) -- But drop in immunoglobulin levels less robust (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 10, 2017 Category: Rheumatology Source Type: news

Current and Novel Vasculitis Biomarkers Current and Novel Vasculitis Biomarkers
Dr Desai comments on a study reviewing biomarkers that can diagnose, prognosticate, and monitor disease activity in antineutrophil cytoplasm antibody-associated vasculitis.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 6, 2017 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

Mid-face toddler excoriation syndrome (MiTES): a new paediatric diagnosis - Srinivas SM, Gowda VK, Owen CM, Moss C, Hiremagalore R.
Chronic ulcerating lesions on the face are rarely seen in toddlers. Blistering disease, vasculitis, infections and self-mutilation due to neurometabolic disease can usually be excluded on clinical and histological grounds. In the absence of identifiable di... (Source: SafetyLit)
Source: SafetyLit - January 5, 2017 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

New Risks Posed by Vancomycin Use in Cataract Surgery New Risks Posed by Vancomycin Use in Cataract Surgery
Dr Roger Steinert shares the latest information on hemorrhagic occlusive retinal vasculitis, a new and potentially devastating complication.Medscape Ophthalmology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 12, 2016 Category: Allergy & Immunology Tags: Ophthalmology Commentary Source Type: news

FDA grants breakthrough therapy designation for Roche ’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra/RoActemra ® (tocilizumab) for giant cell arteritis (GCA), a chronic, potentially life-threatening autoimmune condition. (Source: Roche Investor Update)
Source: Roche Investor Update - October 5, 2016 Category: Pharmaceuticals Source Type: news

FDA grants breakthrough therapy designation for Roche ’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra/RoActemra ® (tocilizumab) for giant cell arteritis (GCA), a chronic, potentially life-threatening autoimmune condition. (Source: Roche Media News)
Source: Roche Media News - October 5, 2016 Category: Pharmaceuticals Source Type: news

Recommendations for Managing ANCA-Associated Vasculitis Recommendations for Managing ANCA-Associated Vasculitis
What are the best strategies for managing antineutrophil cytoplasmic antibody-associated vasculitis? Find out what the experts recommend.Annals of the Rheumatic Diseases (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 3, 2016 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

Vancomycin in Cataract Procedures May Cause Blindness Vancomycin in Cataract Procedures May Cause Blindness
Researchers have documented 35 eyes with severe hemorrhagic occlusive retinal vasculitis after treatment with vancomycin during cataract procedures.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Vasculitis
Title: VasculitisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/11/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - August 11, 2016 Category: Rheumatology Source Type: news

Temporal (Giant Cell) Arteritis: 3 Questions You were Afraid to Ask
The large vessel vasculitis is more common among older adults and extremely dangerous if missed. Get answers to 3 questions you should ask. (Source: ConsultantLive)
Source: ConsultantLive - July 20, 2016 Category: Internal Medicine Authors: Gregory W. Rutecki, MD Source Type: news

EULAR: New Recommendations for Treating Vasculitis (CME/CE)
(MedPage Today) -- "This clearly reflects the standard of care," says U.S. expert (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 29, 2016 Category: Consumer Health News Source Type: news

Report: ChemoCentryx’s CCX168 can meet major unmet needs in vasculitis patients
CCX 168, a small molecule being developed by US-based, clinical-stage biopharmaceutical company ChemoCentryx, is a potential treatment for a number of major unmet needs in vasculitis patients and has significant advantages over its competitors, accor… (Source: Drug Development Technology)
Source: Drug Development Technology - May 26, 2016 Category: Pharmaceuticals Source Type: news

Rare Vasculitis Less So in Minorities (CME/CE)
(MedPage Today) -- Takayasu arteritis more common in immigrants to Norway (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 19, 2016 Category: Primary Care Source Type: news

Arzerra: An Alternate Tx in Vasculitis (CME/CE)
(MedPage Today) -- B-cell depletion successful in patients who didn't respond to Rituxan (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 3, 2016 Category: Primary Care Source Type: news